Trial Profile

Efficacy and safety of Axicabtagene ciloleucel in patients with relapsed/refractory large B-cell lymphoma: US Lymphoma CAR-T Consortium Study

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 11 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Axicabtagene ciloleucel (Primary)
Indications B-cell lymphoma; Diffuse large B cell lymphoma; Endometrial cancer; Follicular lymphoma; Lung cancer; Mesothelioma; Sarcoma; Squamous cell cancer; T-cell lymphoma
Focus Adverse reactions; Therapeutic Use

01 Oct 2022 Results evaluating severity of Cytokine Release Syndrome Influencing Outcome after Axicabtagene Ciloleucel for Large B cell Lymphoma,published in the Clinical Lymphoma, Myeloma & Leukemia
01 Jan 2022 Results from cohort at a median follow up of 32.4 months, as well as late outcomes of interest including cytopenias, infections and secondary malignancie published in the Life Sciences
14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com